GS 5894
Alternative Names: GS-5894Latest Information Update: 17 May 2024
At a glance
- Originator Gilead Sciences
- Class Antiretrovirals; Pyrimidines; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HIV infections
Most Recent Events
- 17 May 2024 Chemical structure information added
- 04 Mar 2024 Gilead Sciences completes phase-I clinical trials in HIV infections in Thailand and USA (PO) (NCT05585307)
- 03 Mar 2024 Pharmacodynamics and pharmacokinectics data from preclinical studies in HIV-1 infections presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI-2024)